Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: GlobeNewswire
NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the TD Cowen 46th Annual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma e
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics (DNTH) had its price target raised by Guggenheim from $100.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]Seeking Alpha
- Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $46.00 to $55.00. They now have an "outperform" rating on the stock.MarketBeat
DNTH
Earnings
- 11/5/25 - Miss
DNTH
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/4/26 - Form 4
- DNTH's page on the SEC website